Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Five Low Cost Ways To Prevent Cancer
In today"s troubled economy, saving money is a hot topic. No matter what gets cut from your budget, however, experts at The University of Texas M. D. Anderson Cancer Center believe that healthy choices to prevent cancer shouldn"t be on the list.
generic viagra online
Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for levonorgestrel tablets, 0.75 mg, for women seventeen years and younger. Levonorgestrel is the generic equivalent to Duramed Pharmaceuticals" PLAN B(R), which is indicated for the prevention of pregnancy following unprotected intercourse or contraceptive failure. This product is approved for prescription use only. The Company intends to market the product under the trade name Next Choice(TM) and plans to launch the product shortly. For the 12-months ending March 2009, PLAN B(R) had total U.S. sales of approximately $123 million, of which approximately ten percent are attributable to prescription sales, according to IMS sales data. PLAN B(R) over-the-counter (O.T.C.) new product exclusivity expires on August 24, 2009.
News of the day
Fecal Incontinence And Quality Of Life
Fecal incontinence (FI) is a normal part of aging, or the perception that no treatment is available. Doctors may fail to comprehend patient hints about diarrhea and FI or may be reluctant to ask about fecal leakage, perhaps because of their own embarrassment or the perception that FI is a trivial concern.
Public Health

U.S. Doubles Annual Malawi HIV/AIDS Support To $45M

The U.S. government recently announced a commitment to double its support for Malawi"s efforts to fight HIV/AIDS to $45 million annually, Xinhua reports (Xinhua, 6/2). The "Partnership Framework" was established after U.S. Ambassador to Malawi Peter Bodde and Malawi"s Secretary to the Treasury Randson Mwadiwa signed a "landmark document" on May 18 that sets the foundation for a new framework for the U.S.-Malawi collaboration to combat HIV/AIDS, according to a statement from the U.S. Embassy in Malawi. The document calls for "increased focus on reducing new HIV infections, while maintaining ongoing activities aimed at improving the quality of treatment and care and mitigating the impacts on individuals and households," according to the release, which adds that objectives should be achieved within a context of "enhanced Malawian leadership and ownership of the overall response." At the signing of the partnership, Bodde said the framework with Malawi "will serve as the model for those that follow in other countries" (Embassy of the U.S., Lilongwe, Malawi release). Malawi is the first country to sign an agreement with the U.S. following the 2008 reauthorization of PEPFAR. According to Xinhua, about 200,000 HIV-positive people in Malawi are receiving free antiretroviral treatments. There are about one million people living with HIV/AIDS in the country (Xinhua, 6/2). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009